Adverum Biotechnologies Inc


ADVM

Price

7.76


Change

-0.1


High

NA


Low

NA


Avg Volume

498,718


PE Ratio

NA


52 Week High

29.7


52 Week Low

7.4



Profile

Adverum Biotechnologies, publicly traded is a clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, designed as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. On May 12, 2016, Adverum formed as a company after the closing on a transaction with Annapurna Therapeutics. The company announced its common stock will begin trading on Nasdaq under the symbol ADVM as of the open of market.


Top Streaming News


Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.

Data provided by IEX Cloud

About

Copyright © 2020 Finaza.IO. All Rights Reserved.